9 March 2022 - NICE has published evidence based recommendations on dapagliflozin propanediol monohydrate (Forxiga) for adults with chronic kidney disease.

Dapagliflozin propanediol monohydrate is recommended as an option for the treatment of adults with chronic kidney disease. It is recommended only if:

• It is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme  inhibitors or angiotensin-receptor blockers, unless these are contraindicated, and
• People have an estimated glomerular filtration rate of 25 mL/min/1.73 m2 to 75 mL/min/1.73 m2 at the start of treatment and have type 2 diabetes or have a urine albumin-to-creatinine ratio of 22.6 mg/mmoL or more

Read NICE final appraisal determination for dapagliflozin propanediol monohydrate